One phase two trial (mean age 58, with no upper age limit) demonstrated mean reduction in body weight of 15.6% in participants taking CagriSema, compared to 5.1% and 8.1% with semaglutide and cagrilintide in monotherapy, respectively, over 32 weeks
35 Regional prevalence varies significantly due to ethnic, genetic, and lifestyle factors, with the lowest rates observed in Western Europe and the highest in Latin America, ranging from 25.1% to 44.3%
Instead, they could be a result of the rapid changes to metabolism that happen when a person starts taking semaglutide
Typically taken as a tablet, levothyroxine replaces the bodys thyroid hormone in individuals with deficiency, which can be caused by the autoimmune disorder Hashimoto thyroiditis, surgical removal of the thyroid, or other conditions